MATEUS MISTIERI SIMABUKURO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
41 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 41
- Autoimmune encephalitis and anti-GAD/GABA-A receptor antibodies(2015) SIMABUKURO, Mateus M.
- Rapidly progressive dementia in a neurologic unit of a tertiary hospital in Brazil(2015) STUDART NETO, A.; SOARES NETO, H.; SIMABUKURO, M.; GONCALVES, M.; FORTINI, I. D. A.; CASTRO, L.; NITRINI, R.
- SLEEP DISORDER, CHOREA, AND DEMENTIA ASSOCIATED WITH IgLON5 ANTIBODIES(2015) SIMABUKURO, Mateus M.; SABATER, Lidia; ADONI, Tarso; CURY, Rubens Gisbert; HADDAD, Monica Santoro; MOREIRA, Camila Hohi; OLIVEIRA, Imam; BOAVENTURA, Mateus; ALVES, Rosana Cardoso; SOSTER, Leticia Azevedo; NITRINI, Ricardo; GAIG, Carles; SANTAMARIA, Joan; DALMAU, Josep; GRAUS, Francesc
- Clinical manifestations of the anti-IgLON5 disease(2017) GAIG, Carles; GRAUS, Francesc; COMPTA, Yarko; HOGL, Birgit; BATALLER, Luis; BRUGGEMANN, Norbert; GIORDANA, Caroline; HEIDBREDER, Anna; KOTSCHET, Katya; LEWERENZ, Jan; MACHER, Stefan; MARTI, Maria J.; MONTOJO, Teresa; PEREZ-PEREZ, Jesus; PUERTAS, Inmaculada; SEITZ, Caspar; SIMABUKURO, Mateus; TELLEZ, Nieves; WANDINGER, Klaus-Peter; IRANZO, Alex; ERCILLA, Guadalupe; SABATER, Lidia; SANTAMARIA, Joan; DALMAU, JosepObjective: To report the presentation, main syndromes, human leukocyte antigen (HLA) association, and immunoglobulin G (IgG) subclass in the anti-IgLON5 disease: a disorder with parasomnias, sleep apnea, and IgLON5 antibodies. Methods: This was a retrospective clinical analysis of 22 patients. The IgG subclass was determined using reported techniques. Results: Patients' median age was 64 years (range 46-83). Symptoms that led to initial consultation included sleep problems (8 patients; 36%), gait abnormalities (8; 36%), bulbar dysfunction (3; 14%), chorea (2; 9%), and cognitive decline (1; 5%). By the time of diagnosis of the disorder, 4 syndromes were identified: (1) a sleep disorder with parasomnia and sleep breathing difficulty in 8 (36%) patients; (2) a bulbar syndrome including dysphagia, sialorrhea, stridor, or acute respiratory insufficiency in 6 (27%); (3) a syndrome resembling progressive supranuclear palsy (PSP-like) in 5 (23%); and (4) cognitive decline with or without chorea in 3 (14%). All patients eventually developed parasomnia, sleep apnea, insomnia, or excessive daytime sleepiness. HLA-DRB1*10:01 and HLA-DQB1*05:01 were positive in 13/15 (87%) patients; the DRB1*10:01 allele was 36 times more prevalent than in the general population. Among 16 patients with paired serum and CSF samples, 14 had IgLON5 antibodies in both, and 2 only in serum (both had a PSP-like syndrome). Twenty of 21 patients had IgG1 and IgG4 antibodies; the latter predominated in 16. Conclusions: Patients with IgLON5 antibodies develop a characteristic sleep disorder preceded or accompanied by bulbar symptoms, gait abnormalities, oculomotor problems, and, less frequently, cognitive decline. IgG4 subclass antibodies predominate over IgG1; we confirm a strong association with the HLA-DRB1*10:01 allele.
- The importance of recognizing faciobrachial dystonic seizures in rapidly progressive dementias(2016) SIMABUKURO, Mateus Mistieri; NÓBREGA, Paulo Ribeiro; PITOMBEIRA, Milena; CAVALCANTE, Wagner Cid Palmeira; GRATIVVOL, Ronnyson Susano; PINTO, Lécio Figueira; CASTRO, Luiz Henrique Martins; NITRINI, RicardoABSTRACT Background: Creutzfeldt-Jakob Disease (CJD) is the prototypical cause of rapidly progressive dementia (RPD). Nonetheless, efforts to exclude reversible causes of RPD that mimic prion disease are imperative. The recent expanding characterization of neurological syndromes associated with antibodies directed against neuronal cell surface or sympathic antigens, namely autoimmune encephalitis is shifting paradigms in neurology. Such antigens are well known proteins and receptors involved in synaptic transmission. Their dysfunction results in neuropsychiatric symptoms, psychosis, seizures, movement disorders and RPD. Faciobrachial dystonic seizure (FBDS) is a novel characterized type of seizure, specific for anti-LGI1 encephalitis. Objective: In order to improve clinical recognition we report the cases of two Brazilian patients who presented with characteristic FDBS (illustrated by videos) and anti-LGI1 encephalitis. Methods: We have included all patients with FBDS and confirmed anti-LGI1 encephalitis and video records of FDBS in two tertiary Brazilian centers: Department of Neurology of Hospital das Clínicas, Sao Paulo University, Sao Paulo, Brazil and Hospital Geral de Fortaleza, Fortaleza, Brazil between January 1, 2011 and December 31, 2015. Results: Both patients presented with clinical features of limbic encephalitis associated with FBDS, hyponatremia and normal CSF. None of them presented with tumor and both showed a good response after immunotherapy. Conclusion: FBDSs may be confounded with myoclonus and occurs simultaneously with rapid cognitive decline. Unawareness of FDBS may induce to misdiagnosing a treatable cause of RPD as CJD.
bookPart Neoplasias benignas e malignas do sistema nervoso central(2021) STERMAN NETO, Hugo; NEVILLE, Iuri Santana; SIMABUKURO, Mateus Mistieri- Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature(2020) OLIVEIRA, Marcos C. B.; BRITO, Marcelo H. de; SIMABUKURO, Mateus M.Immune checkpoint inhibitors (ICI) are a novel class of antineoplastic treatment that enhances immunity against tumors. They are associated with immune adverse events, and several neurological syndromes have been described, including multiple sclerosis and atypical demyelination. We performed a systematic literature review of case reports with neurological immune adverse events that presented with central nervous system demyelination, up to December 2019. We found 23 cases: seven with myelitis, four isolated optic neuritis, one neuromyelitis optica spectrum disorder, five multiple sclerosis, and six with atypical demyelination. Ipilimumab was the most frequently used ICI (11/23). The median time to develop symptoms from the onset of ICI was 6.5 weeks [range 1.0-43.0], and from last ICI dose was 14 days [range 0-161]. Anatomopathological examination was performed in four cases, with the finding of a T-cell mediated immune response. Outcomes were generally favorable after immunosuppression: 18 patients had improvement or a full recovery, three patients did not respond to treatment, three patients died, and in one, treatment was not reported. We describe the patients' clinical presentation, treatment administered, and outcomes. We further speculate on possible pathophysiological mechanisms and discuss potential treatments that may be worth investigating.
- Clinical Features and Inflammatory Markers in Autoimmune Encephalitis Associated With Antibodies Against Neuronal Surface in Brazilian Patients(2019) NOBREGA, Paulo Ribeiro; PITOMBEIRA, Milena Sales; MENDES, Lucas Silvestre; KRUEGER, Mariana Braatz; SANTOS, Carolina Figueiredo; MORAIS, Norma Martins de Menezes; SIMABUKURO, Mateus Mistieri; MAIA, Fernanda Martins; BRAGA-NETO, PedroAcute encephalitis is a debilitating neurological disorder associated with brain inflammation and rapidly progressive encephalopathy. Autoimmune encephalitis (AE) is increasingly recognized as one of the most frequent causes of encephalitis, however signs of inflammation are not always present at the onset which may delay the diagnosis. We retrospectively assessed patients with AE associated with antibodies against neuronal surface diagnosed in reference centers in Northeast of Brazil between 2014 to 2017. CNS inflammatory markers were defined as altered CSF (pleocytosis >5 cells/mm(3)) and/or any brain parenchymal MRI signal abnormality. Thirteen patients were evaluated, anti-NMDAR was the most common antibody found (10/13, 77%), followed by anti-LGI1 (2/13, 15%), and anti-AMPAR (1/13, 7%). Median time to diagnosis was 4 months (range 2-9 months). Among these 13 patients, 6 (46.1%) had inflammatory markers and when compared to those who did not present signs of inflammation, there were no significant differences regarding the age of onset, time to diagnosis and modified Rankin scale score at the last visit. Most of the patients presented partial or complete response to immunotherapy during follow-up. Our findings suggest that the presence of inflammatory markers may not correlate with clinical presentation or prognosis in patients with AE associated with antibodies against neuronal surface. Neurologists should be aware to recognize clinical features of AE and promptly request antibody testing even without evidence of inflammation in CSF or MRI studies.
conferenceObject BRAIN METABOLIC IMAGING PATTERNS IN DIFFERENT AUTOANTIBODY-MEDIATED ENCEPHALITIS: A SERIES OF 10 CASES(2016) COUTINHO, Artur; SORIANO, Marianne; SIMABUKURO, Mateus; NUNES, Rafael; ONO, Carla; CASTRO, Luis; BUCHPIGUEL, Carlos- Teaching NeuroImages: Limbic encephalitis associated with relapsing polychondritis(2016) SIMABUKURO, Mateus Mistieri; LUCATO, Leandro Tavares; SHINJO, Samuel Katsuyuki; FLORES, Wellington Lima; CASTRO, Luiz Henrique MartinsA 43-year-old man presented with subacute fever, costochondritis, headache, seizures, and amnesia. Brain MRI (figure) showed bilateral temporal lobe hyperintensities. CSF revealed 105 white cells/mm(3) (77% lympho-monocytes), elevated protein, and normal glucose. Infection and paraneoplastic/autoimmune workup was negative. He improved after corticosteroid treatment.